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MELANOCORTIN-4 RECEPTOR (MC4R) VARIANTS AND MEASURES OF 
ADIPOSITY IN THE GENERAL POPULATION 
 
Mechele Lee, M.S. 
University of Pittsburgh, 2006
 
Background: As the prevalence of obesity has steadily increased, it has rapidly emerged 
as a major public health concern due to a high risk of morbidity and mortality.  Rare missense 
and nonsense mutations in the melanocortin-4 receptor (MC4R) gene are a cause of genetic 
forms of severe obesity, and targeted disruption of the mouse MC4R leads to obesity.  The role 
of variation at the MC4R locus in influencing interindividual variation in body size and 
composition in the general population is controversial. 
Objective: To test the hypothesis that polymorphic variation at the MC4R locus is 
significantly associated with measures of adiposity in the general population. 
Methods: Two single nucleotide polymorphisms, -4599 T>G and -4850 T>C, in the 5’-
flanking region of MC4R were verified by resequencing in 16 individuals and genotyped in the 
larger sample by fluorescence polarization.  1,099 healthy, non-Hispanic white volunteers, age 
30-54 years, were recruited from the Pittsburgh community.  A medical and demographic history 
was collected and anthropomorphic measures were determined.  ANOVA was used to assess the 
relationship between genotype and metabolic parameters. 
Results: BMI was greater in participants having a -4599 G allele (GG + TG genotypes) 
than among TT homozygotes (p < 0.03), and this association was of similar magnitude in both 
men (BMI 28.2 vs. 27.4) and women (BMI 26.5 vs. 25.9).  Nominally defined overweight (BMI 
≥ 27) also varied significantly (Chi-square = 6.874, p < 0.04) across -4599 genotypes (GG: 
52.4%; TG: 46.8%, TT: 40.6%).  A similar relationship was seen for the -4850 T>C SNP (CC: 
53.2%; TC: 48.0%; TT: 41.4%; Chi-square = 6.256, p < 0.05).  Finally, subjects with any -4599 
G allele had significantly higher weight (177.0 vs. 172.8; p < 0.05) and percent of body fat 
(29.8% vs. 28.8%; p < 0.04).  Greater waist circumference was also significantly associated with 
both the -4599 G allele (36.3 vs. 35.6; p < 0.04) and the -4850 C allele (36.4 vs. 35.6; p < 0.05). 
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Conclusion: Common variation in the 5’-flanking region of the MC4R gene is 
significantly associated with measures of adiposity in men and women in the general population.   
 v 
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1.0  INTRODUCTION 
1.1 OVERWEIGHT AND OBESITY - BACKGROUND 
Obesity is a complex, multi-factorial chronic disease that is characterized by an excess 
accumulation of body fat.  While everyone needs a certain amount of body fat for stored energy, 
heat insulation, shock absorption, and other functions, obesity increases the risk of illness from 
about 30 serious medical conditions.  Frequently, obesity is defined by body mass index (BMI), 
which is thought to generally correlate to measurements of body fat.  BMI is a calculation based 
on both height and weight.  Traditionally, a BMI of 30 kg/m2 or higher is indicative of obesity, 
and a BMI of 40 kg/m2 or greater is classified as morbid obesity.  “Overweight” is a less severe 
condition that corresponds to a BMI between 25 and 29.9 kg/m2. 
Overweight and obesity result from an energy imbalance when more calories are 
consumed from a person’s diet than are expended through physical activity.  The cause of the 
imbalance may differ from one person to another; Environmental (social and cultural), genetic, 
physiological, metabolic, behavioral, and psychological components all play a role.  Simply put, 
obesity has a strong familial component and is promoted by an environment of decreased 
physical activity and high-calorie, low-cost foods. 
The prevalence of overweight and obesity is increasing rapidly in both developing and 
developed countries, worldwide.72  In the United States, the number of overweight and obese 
Americans has increased relentlessly since 196060,61 (see Table 1).  The latest data indicate that 
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64.5% of adult Americans (approximately 127 million people) are categorized as being 
overweight or obese.  About 60 million of those are classified as obese, constituting 1/3 of the 
adult American population.  Another 9 million Americans are considered morbidly obese. 
Table 1. Increase in Prevalence of Overweight, Obesity, and Morbid Obesity among U.S. Adults 
  Overweight Obesity Severe Obesity 
  (BMI ≥ 25) (BMI ≥ 30) (BMI ≥ 40) 
1999 to 2000 64.5% 30.5% 4.7% 
1988 to 1994 56.0% 23.0% 2.9% 
1976 to 1980 46.0% 14.4% No Data 
Source: CDC, National Center for Health Statistics, National Health and Nutrition Examination Survey.  Health, United States, 2002. 
Flegal et. al. JAMA. 2002;288:1723-7.  NIH, National Heart, Lung, and Blood Institute, Clinical Guidelines on the Identification, 
Evaluation and Treatment of Overweight and Obesity in Adults, 1998. 
 
As the prevalence of obesity has steadily increased, it has rapidly emerged as a major 
public health concern62,63 due to significantly increased mortality2 and a high risk of morbidity.63  
Because obesity disrupts lipid and glucose homeostasis, it is frequently associated with 
dyslipidemia, hypertension, diabetes mellitus, atherosclerosis, and cardiovascular 
disease47,55,63,82,85 and often leads to a diagnosis of the metabolic syndrome.70  In 1999, Colditz 
estimated that obesity-related morbidity may account for 9.4% of U.S. healthcare costs,17 with 
approximately $100 billion total cost in 1995 and $52 billion in direct medical costs.88  Each 
year, obesity causes at least 300, 000 excess deaths in the U.S.,2 making it the second leading 
cause of unnecessary deaths.  Even more alarming is the dramatic increase in childhood obesity 
and comorbidities (particularly type 2 diabetes) in industrialized countries.21  In the U.S., the 
percentage of young people who are overweight has more than tripled since 1980; Currently 16% 
of children and teens aged 6-19 years are considered overweight. 
Many treatments for obesity are available, including dietary therapy, physical activity, 
behavior therapy, drug therapy, combined therapy, and surgery.  Surgical treatments have 
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dramatically increased in popularity and are used to modify the stomach and/or intestines to 
decrease the amount of food that can be eaten and sometimes absorbed.  However, obesity has 
proven difficult to treat, as indicated by the continued rise in prevalence.  It is important to 
identify the pathophysiologic mechanisms underlying this disease as a means of identifying new 
prevention strategies34 and treatment targets.21   
1.2 GENETICS OF OBESITY 
Although obesity was once thought to be simply a behavioral disorder, recent research 
has shown that several genetic factors play a role in regulating energy balance via the 
neuroendocrine system.48,57,76  Twin studies have estimated the heritable component of obesity 
between 30 – 70% with the typical estimate at 50%.53  Some studies have shown that heritability 
rates for obesity may equal that of height and possibly surpass that of almost all other major 
diseases that have been studied.3,9,27,71,81
The neuroendocrine system regulates energy balance by controlling appetite and food 
intake and utilization.10,57,76  Once adipose tissue accumulates, this system prevents it from 
diminishing,48 which proved useful for defending against body weight loss when food was 
scarce.  With the current abundance of food in industrialized nations, humans appear to have 
only weak physiological mechanisms to defend against body weight gain.34  Neurons in the 
hypothalamus regulate appetite and basal metabolic activity by mediating signaling of the 
adipostatic hormone leptin.12,22,23,91 
Ravussin and Bogardus concluded that among different populations, the prevalence of 
obesity is largely determined by environmental factors, but that among individuals from the same 
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population living in a given environment, the variability in body size and composition is mostly 
related to genetically determined response to that environment.72   
Linkage studies have shown major obesity susceptibility loci to be located on 
chromosomes 2, 4, 5, 10, 11, and 20.30,50,72,80  Possible candidate genes include leptin, leptin 
receptor, melanocortin-4 receptor (MC4R), prohormone convertase 1 (PCSK1), and 
proopiomelanocortin (POMC).6,9  Common obesity is likely to be a polygenic disorder, but 
monogenic causes have been described.6,48  To date, MC4R mutations cause the most common 
form of monogenic obesity seen in humans.26,31,68,70
1.3 MELANOCORTIN-4 RECEPTOR (MC4R) - BACKGROUND 
Melanocortins are a group of ligands derived from proopiomelanocortin (POMC) by 
enzymatic processing.14  The four major ligands are α-melanocyte-stimulating-hormone (α-
MSH), β-MSH, γ-MSH, and adrenocorticotropic hormone (ACTH).12,14,41,68  The melanocortin 
system is also composed of five melanocortin receptors and two antagonists, agouti and agouti-
related protein (AGRP). 12,14,41   
The melanocortin system has multiple functions, including roles in memory and learning, 
thermoregulation, analgesia, stress response, inflammation, pigmentation, and feeding 
behavior.14  Leptin, a protein hormone that plays an important role in regulating body weight, 
metabolism, and reproductive function, is responsible for linking peripheral adipostatic signals to 
central melanocortinergic neurons.59,68,75  Leptin is released from adipose tissue and crosses the 
blood-brain barrier to both inhibit the melanocortin receptor antagonist AGRP and to activate 
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POMC expression.19,38  POMC is then cleaved to generate α-MSH, β-MSH, γ-MSH, and ACTH 
which induce satiety and an elevated energy expenditure32 by binding to melanocortin receptors. 
The melanocortin receptors (MC1R, MC2R, MC3R, MC4R, and MC5R) belong to the G-
protein coupled receptor (GPCR) superfamily class A.14  When the melanocortin ligands bind to 
the receptors, stimulatory G-proteins are released which activate adenylate cyclase.12,14  This 
results in an increase in cellular cyclic AMP (cAMP).12  The central melanocortin system 
receives several inputs from both central and peripheral appetite regulating pathways that can 
modulate the effects of the melanocortin system on food intake and energy expenditure.32,41 
In 1993, Gantz et al. reported the cloning, expression, and gene localization of the 
melanocortin-4 receptor (MC4R).28  MC4R is a 332-amino acid protein which is primarily 
expressed in the brain.82  MC4R is located on chromosome 18q22 and is encoded by a single 
exon.49  Of the five receptors, MC4R is the most conserved with ~94% homology among 
mammals.56  Although it is found throughout the central nervous system,51,56,82 the highest level 
of MC4R expression is observed in the hypothalamus,56,68,78 which is a primary brain region for 
regulating food intake and body weight.22,23,46,91  High levels of melanocortin ligands are also 
seen in the arcuate nucleus of the hypothalamus.68  
1.4 MC4R - ROLES 
MC4R functions include regulating body weight, food behaviors, sexual function, HPA 
axis activity, emotional states, pain, drug addiction, and stress response.14  In 1997, Huszar et al. 
was the first to establish that MC4R is a critical component of the homeostatic circuit that 
regulates energy balance in mammals.40  Activation of MC4R has been shown to inhibit appetite 
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and increase basal metabolic rate (BMR) while antagonism leads to hyperphagia and decreased 
metabolic activity.12,51,78 
ACTH and α-MSH are the melanocortin ligands that have the highest binding affinity to 
MC4R.14  In the fed state, levels of these peptides increase due to activation of POMC resulting 
from high concentrations of circulating leptin.68  Upon binding to MC4R, ACTH and α-MSH 
both have an inhibitory effect on feeding and possibly cause increased energy expenditure and 
weight loss.8,32,41   
AGRP is normally suppressed by leptin in the fed state.87  In the starved state, circulating 
levels of leptin decrease, leading to decreased POMC activity and increased AGRP activity.  
Together, these events lead to a powerful inhibition of MC4R signaling and therefore promote 
food intake.1,59,68,87  AGRP has little intrinsic signaling activity and primarily acts by preventing 
melanocortins from binding to MC4R.5,67,77,89   
1.5 MC4R - STUDIES 
It was first established in 1986 that administration of ACTH and α-MSH markedly 
inhibited spontaneous feeding in rats.41,69  Studies have also shown that central administration of 
MC4R-specific antagonists causes an increase in feeding and obesity.16,44  When an antagonist 
and agonist were given together to mice, it was noted that the inhibition of food intake was 
reversed.45
In 1997, it was first noted that MC4R knock out mice on an ad libitum diet are obese and 
hyperphagic and also have increased length and hyperinsulinemia compared to wild type mice.40  
Interestingly, heterozygotes have a body weight intermediate between wild type and MC4R-null 
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mice,15,32,40,79 suggesting that MC4R is quantitatively important in the regulation of energy 
balance.68  Whether MC4R is required solely for feeding response or also plays a role in 
metabolic and activity responses remains somewhat controversial.11,14,15,19,20,40,51,79,68  One study 
showed that MC4R knock out mice show a predisposition to store calories as adipose tissue.79   
In humans, MC4R deficiency has been associated with hyperphagia,25,26,49,55,68 obesity 
(including increased fat32,74 and lean body mass49),12,20,25,35,52,78,84 increased bone mineral 
density,49 accelerated linear growth,26 and hyperinsulinemia.74  Although MC4R knock out mice 
demonstrate reduced energy expenditure, impairments in basal metabolic rate do not seem to be 
associated with MC4R mutations in humans.26,55  One study did show, however, that a functional 
MC4R is needed for acute regulation of activity-based energy expenditure in response to changes 
in diet.51  A phenotypic assessment of individuals with haploinsufficiency MC4R mutations done 
by Sina et al. showed no evidence of diabetes or hypertention, a gynoid pattern of fat 
distribution, and a low incidence of binge eating disorder.78   
Linkage studies have provided suggestive evidence of linkage between BMI66 and body 
fat13,65 on chromosome 18q21, flanking the MC4R region. 
Mutations in the MC4R gene are considered to be the most common form of monogenic 
obesity in humans,25,26,36,70,78,85 accounting for ~5% of severe obesity.70  More than 70 variants 
have been reported in various patient cohorts.83  At least 34 are functionally relevant frameshift, 
nonsense, and missense mutations, most of which result in partial or total loss of function of the 
MC4R gene.35,37,51,52,64,90  However, all mutations are rare, with heterozygosity rates <1% for any 
single mutation12,35 and combined mutation frequencies of 2-6% in extremely obese 
individuals.12,25,26,33,35,36,37,55,85  Due to the small population frequency of mutation carriers, 
MC4R mutations appear to have a low epidemiological but high individual relevance.35   
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Some studies have found that obesity that is associated with MC4R mutations tends to be 
limited to early-onset cases,7,43,55,78,85 and that the phenotype becomes less prominent with 
age.25,55   
Functional studies have shown that the regulation of body weight in humans is sensitive 
to variations in the amount of functional MC4R,25,26,40,84 suggesting a codominant pattern of 
inheritance.25,47  Although most of the MC4R mutations identified to date lead to a loss of 
function resulting in obesity,35,37,51,52,64,90 at least one variant (Val103Ile) has been shown to 
cause a moderate gain of function and reduced body weight.29,33,35,73   
Although MC4R mutations are generally considered a “monogenic” form of obesity, 
multiple studies have identified mutation carriers who are only moderately overweight or even 
lean.20,25,26,64,78,83,85   The limited penetrance and variable expression of the MC4R mutations may 
be due to a partial reduction in receptor function resulting from haploinsufficiency18,78 or a 
dominant negative mechanism.85  It is clear that obesity is a complex trait and that other genetic 
an environmental factors are operative.18,20,21,35,64,78   
MC4R mutations are considered causative factors in a significant proportion of morbid 
obesity cases,43 however their role in common obesity and normal weight regulation is thought to 
be negligible due to the low frequency of mutations in the general population.12  It remains 
possible that common genetic variants in the regulatory regions of the MC4R gene could play a 
role in influencing interindividual variation in body size and composition in the general 
population.52,68,78  
 8 
1.6 PURPOSE AND SIGNIFICANCE 
Because obesity has proven difficult to treat, it is important to identify the 
pathophysiologic mechanisms underlying this disease as a means of identifying new treatment 
targets21 and prevention strategies.  Much has been learned from studies on monogenic obesity, 
however the role of variation at the MC4R locus in influencing interindividual variation in body 
size and composition in the general population remains controversial.52,68,78  To date, MC4R 
mutations have proven to carry a large individual relevance but a small epidemiological 
relevance.35  Therefore, further research involving common polymorphic variation and measures 
of adiposity in the general population would help to elucidate the role of MC4R with regard to 
public health. 
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2.0  MATERIALS AND METHODS 
2.1 SUBJECTS 
Subjects were obtained as part of the Adult Health and Behavior (AHAB) study as a 
community sample of nonpatient volunteers in the Pittsburgh area.  There was no history of 
myocardial infarction, stroke, revascularization procedure (i.e. bypass or angioplasty), angina, 
chronic kidney or liver disease, or psychosis.  Subjects were not on any psychotropic or 
glucocordicoid medications and were not on insulin.  Analyses were based on non-Hispanic 
whites only; 1,099 subjects met these criteria with >97% of subjects successfully genotyped for 
each site.  Approval was obtained from the Institutional Review Board, and all subjects signed 
written informed consent.   
2.2 DNA EXTRACTION 
DNA was extracted from whole blood using a salting-out protocol.58  Briefly, the red 
blood cells and nuclei were lysed and then digested overnight with protease K.  After digestion, 
protein was removed from the DNA by a salting out procedure with NaCl.  The DNA was then 
precipitated with ethanol and suspended in TE buffer for use. 
 10 
2.3 MC4R GENE 
There are 20 validated single nucleotide polymorphisms (SNPs) within approximately 
5kb of the MC4R gene (see figure 1).  Of these, only seven have a minimum allele frequency 
>0.1 (see table 2). 
 
 
Figure 1. Validated SNPs within 5kb of the MC4R Gene 
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Table 2. Validated SNPs within 5kb of the MC4R Gene 
Relative Minimum rs# 
Location Allele Frequency 
Role 
rs9965495 5907 0.411 3' UTR 
rs9966412 5648 0.321 3' UTR 
rs17066836 4992 0.029 3' UTR 
rs17066839 4815 0.028 3' UTR 
rs17700974 3872 0.007 3' UTR 
rs8093815 3080 0.417 3' UTR 
rs6567166 1251 0.014 3' UTR 
rs17773630 1123 0.007 3' UTR 
rs1016862 506 0.000 I169S 
rs2229616 307 0.026 V103I 
rs2282556 292 0.000 G98R 
rs8087522 -896 0.242 5' Flanking 
rs17066842 -1042 0.067 5' Flanking 
rs17066844 -1810 0.007 5' Flanking 
rs7506280 -2543 --- 5' Flanking 
rs6567167 -2576 --- 5' Flanking 
rs8086617 -4008 0.300 5' Flanking 
rs1943217 -4599 0.300 5' Flanking 
rs1943218 -4850 0.265 5' Flanking 
rs9953038 -5081 0.034 5' Flanking 
 
2.4 VERIFICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS 
Resequencing was performed on 16 individuals to screen for SNPs in the MC4R gene 
and regulatory regions.  PCR primers were designed (see Table 3) and obtained from the DNA 
Synthesis Facility at the University of Pittsburgh, and PCR was carried out on an MJ 
thermocycler using the following conditions: 
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           1 Reaction 
10X PCR Buffer (Invitrogen™)  2.5 µL 
1.25mM dNTP (Invitrogen™)  4.0 µL 
50mM MgCl2 (Invitrogen™)   0.75 µL 
20µM Forward Primer   0.375 µL 
20µM Reverse Primer    0.375 µL 
Taq DNA Polymerase (Invitrogen™) 0.1 µL 
dH2O      14.4 µL 
DNA      2.5 µL 
     Total:  25.0 µL 
 
Conditions: 
1. 95˚C for 5 minutes 
2. 35 Cycles 
a. 95˚C for 30 seconds 
b. XX˚C for 15 seconds 
c. 72˚C for 30 seconds 
3. 72˚C for 5 minutes 
4. 10˚C hold forever 
 
Table 3. MC4R Sequencing Primers and Annealing Temperatures for Verification of SNPs 
  Name Sequence (5' to 3') Annealing Temperature 
MC4RSeqF ATGGAGGGTGCTACGAGCAA Coding Region 
MC4RSeqR ATTGGCACCTTGGCGGATG 
50˚C 
MC4RPrF CTCTGGTAACGGGAATGGAG Promoter Region 
MC4RPrR TTCTTCTGGCTCGTAGAG 
47˚C 
MC4RUTR_F TTCCGGTCTCCTTCCACTC 3' UTR Region 
MC4RUTR_R CTGAGCTGTAGCACATGGC 
47˚C 
 
PCR cleanup was performed using Shrimp Alkaline Phosphatase (SAP) and Exonuclease 
I (Exo I) on an MJ thermocycler using the following conditions: 
           1 Reaction 
10X SAP Buffer (USB Corp.)  0.5 µL 
SAP (USB Corp.)    0.5 µL 
Exonuclease (USB Corp.)   0.05 µL 
dH2O      6.45 µL 
PCR      2.5 µL 
     Total:  10.0 µL 
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Conditions: 
1. 37˚C for 35 minutes 
2. 88˚C for 15 minutes 
3. 10˚C hold forever 
 
The sequencing reaction was then performed using dRhodamine Dye Terminator and an 
MJ thermocycler under the following conditions: 
           1 Reaction 
0.8µM Primer     4.0 µL 
5X SeqSaver (Applied Biosystems)  3.0 µL 
dRhodamine (Applied Biosystems)  1.0 µL 
Cleaned PCR     4.0 µL 
     Total:  12.0 µL 
 
Conditions: 
1. 25 Cycles 
a. 96˚C for 10 seconds 
b. 50˚C for 5 seconds 
c. 60˚C for 4 minutes 
2. 10˚C hold forever 
 
Each fragment was sequenced in both the forward and reverse direction. 
The dye terminators were removed from the samples using CleanSEQ beads (Agenecourt 
Bioscience Corp.), ethanol, and a magnetic SPRIPlate. 
The capillary electrophoresis was completed by the Genomics and Proteomics Core 
Laboratories at the University of Pittsburgh using an ABI 3730 DNA Analyzer. 
Sequencing analysis was done using Sequencher software (version 4.2.1, Gene Codes 
Corp.).  Two SNPs in the promoter region were identified: -4599 T>G (allele frequency T=0.70, 
G=0.30; rs#1943217) and -4850 T>C (allele frequency T=0.74, C=0.26; rs#1943218).  No other 
SNPs were seen in the 16 individuals and were therefore presumed to be occurring only at a low 
frequency. 
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2.5 GENOTYPE ANALYSIS 
Genotyping was performed for the -4599 T>G and -4850 T>C using fluorescence 
polarization (FP).39  PCR primers were designed (see Table 4) and ordered from Invitrogen.  
PCR conditions for -4599 T>G were as follows: 
           1 Reaction 
10X PCR Buffer (Invitrogen™)  1.0 µL 
1.25mM dNTP (Invitrogen™)  1.6 µL 
50mM MgCl2 (Invitrogen™)   0.4 µL 
20µM Forward Primer   0.15 µL 
20µM Reverse Primer    0.15 µL 
Taq DNA Polymerase (Invitrogen™) 0.04 µL 
dH2O      5.66 µL 
DNA      1.0 µL 
     Total:  10.0 µL 
 
Conditions: 
1. 95˚C for 5 minutes 
2. 35 Cycles 
a. 95˚C for 30 seconds 
b. 44˚C for 15 seconds 
c. 72˚C for 30 seconds 
3. 72˚C for 5 minutes 
4. 10˚C hold forever 
 
For the -4850 T>C SNP, PCR conditions were as follows: 
           1 Reaction 
10X PCR Buffer (Invitrogen™)  1.0 µL 
1.25mM dNTP (Invitrogen™)  1.6 µL 
50mM MgCl2 (Invitrogen™)   0.3 µL 
20µM Forward Primer   0.15 µL 
20µM Reverse Primer    0.15 µL 
Taq DNA Polymerase (Invitrogen™) 0.04 µL 
dH2O      5.76 µL 
DNA      1.0 µL 
     Total:  10.0 µL 
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Conditions: 
1. 95˚C for 5 minutes 
2. 35 Cycles 
a. 95˚C for 30 seconds 
b. 44˚C for 15 seconds 
c. 72˚C for 30 seconds 
3. 72˚C for 5 minutes 
4. 10˚C hold forever 
 
Table 4. MC4R SNP Primers for Fluorescence Polarization 
MC4R SNP Primers for Fluorescence Polarization 
  Name Sequence (5' to 3') Annealing Temp. 
MC4R-4599F AGCTACTGCAGAGCTGGTG -4599 
MC4R-4599R GAGCACTTGCAAAGCTTGTC 
44˚C 
T>G MC4R-4599Rdet TTAACTAGACATATTTTCCCATTCC   
MC4R-4850F CCACTCTCATCTTCCATC -4850 
MC4R-4850R CTGGGACTTCAGTGTGATCC 
44˚C 
T>C MC4R-4850Rdet ATTGCCATAGATGAATCTAATATAATTTA   
 
SAP/Exonuclease was used for PCR cleanup: 
           1 Reaction 
10X SAP Buffer (USB Corp.)  1.0 µL 
SAP (USB Corp.)    1.0 µL 
Exonuclease (USB Corp.)   0.1 µL 
dH2O      7.9 µL 
PCR      10.0 µL 
     Total:  20.0 µL 
 
Conditions: 
1. 37˚C for 90 minutes 
2. 95˚C for 15 minutes 
3. 10˚C hold forever 
 
Finally, a single base extension step using fluorescently labeled dyes was performed for 
each SNP: 
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MC4R-4599 T>G: 
            1 Reaction 
10X Thermosequenase Buffer (USB Corp.)  1.0 µL 
10µM Detection Primer    1.0 µL 
Thermosequenase (USB Corp.)   0.1 µL 
1:16 A/C Dye (Perkin Elmer Life Science)  0.05 µL 
 r110 C 
 tamra A 
dH2O       7.85 µL 
Cleaned PCR      20.0 µL 
      Total:  30.0 µL 
 
Conditions: 
1. 94˚C for 1 minute 
2. 30 Cycles 
a. 94˚C for 10 seconds 
b. 50˚C for 30 seconds 
3. 10˚C hold forever 
 
MC4R-4850 T>C: 
            1 Reaction 
10X Thermosequenase Buffer (USB Corp.)  1.0 µL 
10µM Detection Primer    1.0 µL 
Thermosequenase (USB Corp.)   0.1 µL 
1:16 A/G Dye (Perkin Elmer Life Science)  0.1 µL 
 r110 A 
 tamra G 
dH2O       7.8 µL 
Cleaned PCR      20.0 µL 
      Total:  30.0 µL 
 
Conditions: 
1. 94˚C for 1 minute 
2. 30 Cycles 
a. 94˚C for 10 seconds 
b. 50˚C for 30 seconds 
3. 10˚C hold forever 
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The samples were read on an Analyst HT plate reader (Molecular Devices) and analyzed 
with Allele Caller™ software (Molecular Devices, version 1.0).  Genotypes were then entered 
into a database. 
2.6 STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS 12.0 software (SPSS Inc.).  Descriptive 
and frequency statistics were used to characterize the population, and analysis of variance 
(ANOVA) was used to check for between group differences for age, family income, and 
education by genotype. 
BMI, weight, height, percent body fat, and fat free mass were averaged over two 
occasions of measurement and analyzed by ANOVA for genotype, sex, and genotype by sex 
associations.  Waist circumference (measured once) was also analyzed.  Three-group (all 3 
genotypes) and 2-group (heterozygous and rare homozygous genotypes combined) analyses were 
done for both SNPs. 
BMI was further evaluated with Chi-square tests by categorizing subjects as normal 
weight (BMI < 27) or overweight (BMI ≥ 27) based on a sample mean BMI of 27.04.  Again, 3-
group and 2-group analyses were done for both SNPs. 
Finally, haplotypes were analyzed for group differences in BMI, weight, height, percent 
body fat, fat free mass, and waist circumference. 
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3.0  RESULTS 
Genotyping at the -4599 T>G locus was successfully completed for 1,082 (98.5%) of the 
subjects.  The G allele was present at a frequency of 30%.  For the -4850 T>C site, 1,070 
(97.4%) subjects were successfully genotyped.  The C allele was seen at a frequency of 24%.  
All genotypes were in Hardy Weinberg equilibrium.  
Subjects in this study were between the ages of 30 and 54 years, with a mean age of 44.7 
years.  On average they had obtained 16 years of education, and the median family income was 
in the range of $50,000 - $64,999 annually (see Table 5 and Appendix A).  Age, family income, 
and education were not significantly associated with sex or genotype for either SNP, and no gene 
by sex interactions were seen (see Table 6).  When genotypes were collapsed into 2 groups (TT 
vs. TG+GG for -4599 T>G and TT vs. TC+CC for -4850 T>C), age was associated with -4850 
T>C status at the p<0.05 level.  
Subjects had a mean BMI of 27.0 kg/m2 and an average weight of 175 pounds (see Table 
5 and Appendix A).  All measures except BMI were distributed normally (see Appendix B).  
BMI is not typically transformed in the literature, and although using the natural log did 
normalize the data, it did not affect the outcome of the results.  No significant statistical 
associations were seen for BMI, weight, height, percent body fat, fat free mass, or waist 
circumference for either SNP (see Table 6).  BMI and percent body fat approached significance 
for the -4599 T>G site with p-values of 0.075 and 0.084, respectively.  For the -4850 T>C site, 
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waist circumference neared significance with a p-value of 0.077.  A sex effect was present for all 
anthropometric measures, but no gene by sex interactions were seen. 
 
Table 5. AHAB Subject Characteristics 
  N Mean 
St. 
Dev. Median Minimum Maximum 
Age (years) 
    Males 
    Females 
1099 
542 
557 
44.71 
44.6 
44.8 
6.77 
6.88 
6.67 
46 
46 
46 
30 
30 
30 
54 
54 
54 
Family Income 
 
    Males 
 
    Females 
1094 
 
541 
 
553     
$50,000-
64,999 
$50,000-
64,999 
$50,000-
64,999     
Individual Income 
 
    Males 
 
    Females 
843 
 
431 
 
412     
$25,000-
34,999 
$35,000-
49,999 
$15,000-
24,999     
Years in School 
    Males 
    Females 
1099 
542 
557     
16 
16 
16 
6 
10 
6 
24 
24 
24 
Education 
    Males 
    Females 
1099 
542 
557     
B.S./B.A. 
B.S./B.A. 
B.S./B.A.     
BMI (kg/m2) 
    Males 
    Females 
1098 
541 
557 
27.04 
27.87 
26.27 
5.31 
4.67 
5.77 
26.20 
27.15 
25.05 
16.9 
18.0 
16.9 
51.4 
51.4 
50.3 
Weight (pounds) 
    Males 
    Females 
1099 
542 
557 
174.94 
195.01 
155.41 
40.79 
35.97 
35.39 
172.00 
189.25 
148.25 
83.3 
118.8 
83.3 
375.0 
375.0 
291.0 
Height (inches) 
    Males 
    Females 
1099 
542 
557 
67.30 
70.10 
64.52 
3.82 
2.63 
2.58 
67.5 
70.0 
64.5 
53.5 
60.25 
53.5 
79.0 
79.0 
72.5 
% Body Fat 
    Males 
    Females 
1097 
540 
557 
29.33 
24.56 
33.95 
9.01 
6.92 
8.38 
28.3 
24.2 
34.2 
4.6 
4.6 
9.0 
54.5 
47.5 
54.5 
Fat Free Mass (pounds) 
    Males 
    Females 
1097 
540 
557 
122.16 
144.98 
100.05 
26.35 
16.12 
10.99 
120.1 
143.5 
98.2 
75.7 
95.1 
75.7 
204.1 
204.1 
141.4 
Waist Circumference (inches) 
    Males 
    Females 
1098 
542 
556 
35.90 
38.97 
32.99 
6.13 
5.27 
5.44 
35.5 
38.5 
32.0 
24.0 
27.0 
24.0 
68.0 
68.0 
52.0 
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Table 6. ANOVA Results 
  3-Group ANOVA 2-Group ANOVA 
  
vs. -4599 
T>G 
vs. -4850 
T>C 
vs. -4599 
T>G 
vs. -4850 
T>C 
Age (years) p = 0.493 p = 0.124 p = 0.300 p = 0.045* 
Family Income p = 0.468 p = 0.513 p = 0.924 p = 0.234 
Individual Income N/A N/A N/A N/A 
Years in School N/A N/A N/A N/A 
Education p = 0.745 p = 0.475 p = 0.439 p = 0.240 
BMI (kg/m*m) p = 0.075 p = 0.115 p = 0.023* p = 0.063 
Weight (pounds) p = 0.134 p = 0.130 p = 0.046* p = 0.080 
Height (inches) p = 0.413 p = 0.503 p = 0.239 p = 0.297 
% Body Fat p = 0.084 p = 0.115 p = 0.039* p = 0.078 
Fat Free Mass (pounds) p = 0.845 p = 0.485 p = 0.580 p = 0.511 
Waist Circumference (inches) p = 0.100 p = 0.077 p = 0.037* p = 0.043* 
* p < 0.05         
 
When genotypes were collapsed into 2 groups for the -4599 T>G site, subjects with a G 
allele (TG + GG genotypes) had significantly higher BMI (Figure 2), weight (Figure 3), percent 
body fat (Figure 4), and waist circumference (Figure 5) at the p<0.05 level.  A gene by sex 
interaction was also seen for height (p = 0.026).  For the -4850 T>C site, the C allele (TC + CC 
genotypes) was associated with increased waist circumference (Figure 6).  All associations were 
of similar magnitude in both men and women. 
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Figure 2. Mean BMI by -4599 T>G Genotype 
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Figure 3. Mean Weight by -4599 T>G Genotype 
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Figure 4. Mean % Body Fat by -4599 T>G Genotype 
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Figure 5. Mean Waist Circumference by -4599 T>G Genotype 
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Figure 6. Mean Waist Circumference by -4850 T>C Genotype 
 
Because BMI is a calculation based on both height and weight, it is possible that one 
measurement may confound the other.  While BMI and weight showed a significant association 
with the -4599 G allele, height did not (p = 0.239; see Figure 7). 
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Figure 7. Mean Height by -4599 T>G Genotype 
A high degree of linkage disequilibrium was noted between the two SNPs (D’ = 0.98; 
83% correlation), however no significant associations were seen. 
Because BMI was the measure of greatest interest, further analysis was done with Chi-
square tests by nominally defining “overweight” as BMI ≥ 27 kg/m2.  For -4599 T>G, 52.4% of 
GG subjects, 46.8% of TG subjects, and 40.6% of TT subjects are classified as overweight (Chi-
square = 6.874, 2 df, p = 0.032; see Figure 8 and Table 7).  A similar relationship is seen for the -
4850 T>C SNP: 53.2% of CC subjects, 48.0% of TC subjects, and 41.4% of TT subjects are 
classified as overweight (Chi-square = 6.256, 2 df, p = 0.044; see Figure 9 and Table 7).  When 
the rare homozygous genotypes were combined with the heterozygotes, the associations became 
stronger for both SNPs (-4599 T>G: Chi-square = 5.800, 1 df, p = 0.016; -4850 T>C: Chi-square 
= 5.671, 1 df, p = 0.017), suggesting a dominant effect. 
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Figure 8. Percent of Overweight (BMI ≥ 27) Subjects by -4599 T>G Genotype 
 
Table 7. Chi-Square Results; Overweight = BMI ≥ 27 
    % overweight       % overweight 
GG 52.4% GG vs. GT NS (p = 0.303) GG/GT 47.9% 
GT 46.8% GT vs. TT NS (p = 0.052)     
TT 40.6% GG vs. TT p = 0.026 TT 40.6% 
-4599 T>G 
  p = 0.032       p = 0.016 
CC 53.2% CC vs. CT NS (p = 0.447) CC/CT 48.8% 
CT 48.0% CT vs. TT p = 0.040     
TT 41.4% CC vs. TT NS (p = 0.072) TT 41.1% 
-4850 T>C 
  p = 0.044       p = 0.017 
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Figure 9. Percent of Overweight (BMI ≥ 27) Subjects by -4850 T>C Genotype 
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4.0  DISCUSSION 
The melanocortin system is important in the regulation of energy balance.8,24  In 
particular, a functioning MC4R has been shown to be necessary to prevent adiposity.6  Mutations 
in the MC4R gene are considered to be the most common form of monogenic obesity in 
humans.25,26,36,70,78,85  Common obesity is thought to be a polygenic disorder48 with no firm 
evidence implicating MC4R loci to date.68  Most MC4R variants are found at very low 
frequencies and have only been identified in obese patients,12 although a few variants have been 
seen in similar frequencies in patients and controls.20  Only two studies have looked at variation 
outside the coding region of MC4R: One study screened 80 base pairs of the promoter,52 and the 
other study was done in Pima Indians.54  It remains possible that genetic polymorphisms in the 
regulatory regions of the MC4R gene may contribute to the risk of developing obesity in the 
general population.52,68,78   
This is the first study to show an association between variation in the MC4R gene with 
measures of adiposity in the general population.  The main finding was a relationship between 
the -4599 G-allele and increased BMI.  Interestingly, an additive effect was seen when subjects 
were categorized as normal (BMI < 27) or overweight (BMI ≥ 27), with the heterozygous group 
having an intermediate percentage of overweight subjects (see Figure 8).  A similar effect was 
seen for the -4850 T>C SNP (see Figure 9). 
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The -4599 G-allele was also associated with elevated weight, percent body fat, and waist 
circumference in this study population, supporting the relationship of MC4R to increases in 
adiposity.  Additionally, waist circumference was significantly associated with the -4850 C-
allele. 
Further research is needed to determine whether the SNPs evaluated in this study have 
functional implications for the MC4R gene.  It is possible that they are in linkage disequilibrium 
with other variants within MC4R or another gene. 
Obesity continues to emerge as a major public health problem.  New information about 
the pathophysiology of obesity is necessary to develop improved strategies and programs for 
weight maintenance and weight reduction.21,62  Mackenzie (2005) states that several 
pharmaceutical companies have programs to develop selective MC4R agonists for the treatment 
of obesity,4 and that it is likely that MC4R agonist drugs will be successfully developed in the 
near future to provide effective anti-obesity treatment.55  
Tailored approaches to prevention will also be enabled with increased knowledge about 
the biological causes of obesity.  Barsh et al. (2000) concludes that if some environmental 
variables manifest themselves only on certain genotypes, efforts to prevent obesity at a public 
health level can be focused on recognition and counseling of susceptible individuals.55  It has 
already been shown that the interaction of diet with MC4R not only involves the regulation of 
appetite, but extends to the regulation of metabolism and physical activity.11  Another study 
found that voluntary exercise, beginning at early ages, may bypass or compensate for the central 
pathway involving MC4R.42  Once the role of MC4R and other genetic factors has been more 
clearly defined, improved strategies for prevention can be developed. 
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Finally, surgical treatments for obesity are becoming commonplace.  Potoczna et al. 
(2004) reported that MC4R variant carriers experienced 5 times more gastric complications per 
patient and treatment year after surgery than did noncarriers, including band problems, decreased 
weight loss, increased need for reoperation and conversion to gastric bypass, and vomiting.70  
Understanding the role of MC4R and its effect on surgical treatment outcome will help doctors 
and patients make educated decisions about treatment options and will hopefully lead to 
healthcare cost savings. 
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5.0  SUMMARY AND CONCLUSION 
As the prevalence of overweight and obesity increase rapidly in both developing and 
developed countries worldwide, the need for greater understanding of their biological origin 
intensifies.  Recent research has shown that several genetic factors play a role in regulating 
energy balance via the neuroendocrine system, and several candidate genes have been identified.  
MC4R mutations are considered to be the most common form of monogenic obesity in humans.  
However, the role of MC4R variation regarding energy homeostasis in the general population is 
controversial. 
This study was among the first to evaluate common polymorphisms in the promoter 
region of MC4R with measures of adiposity in the general population, and the first to show 
statistical associations.  The -4599 G-allele was significantly associated with increased BMI, 
weight, percent body fat, waist circumference, and overall probability of being overweight.  The 
-4850 C-allele was also associated with increased waist circumference and overall probability of 
being overweight. 
If MC4R variation were to be implicated in common obesity, new drug treatments and 
prevention strategies could be identified and utilized.  Reversal of the obesity epidemic and 
related comorbidities would lead to billions of dollars in health care cost savings as well as an 
improved quality of life for the public. 
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APPENDIX A 
SUBJECT CHARACTERISTICS BY GENOTYPE 
Subject Characteristics by MC4R-4599 T>G Genotype 
  TT TG GG 
  N Mean (S.D.) N Mean (S.D.) N Mean (S.D.) 
Age (years) 
    Males 
    Females 
542 
269 
273 
44.90 (6.83) 
44.42 (7.06) 
45.38 (6.57) 
437 
213 
224 
44.38 (6.86) 
44.69 (6.73) 
44.10 (6.99) 
103 
54 
49 
44.83 (6.21) 
44.70 (6.59) 
44.98 (5.82) 
BMI (kg/m2) 
    Males 
    Females 
542 
269 
273 
26.65 (6.83) 
27.43 (4.65) 
25.88 (5.17) 
436 
212 
224 
27.35 (5.81) 
28.21 (4.69) 
26.54 (6.61) 
103 
54 
49 
27.47 (4.64) 
28.29 (4.72) 
26.56 (4.43) 
Weight (pounds) 
    Males 
    Females 
542 
269 
273 
172.75 (38.34)
193.06 (33.26)
152.74 (31.99)
437 
213 
224 
176.91 (44.08)
197.07 (39.02)
157.73 (39.93)
103 
54 
49 
177.48 (39.54) 
196.34 (37.96) 
156.71 (29.85)
Height (inches) 
    Males 
    Females 
542 
269 
273 
67.39 (3.94) 
70.38 (2.54) 
64.45 (2.65) 
437 
213 
224 
67.19 (3.69) 
69.86 (2.67) 
64.66 (2.57) 
103 
54 
49 
67.21 (3.74) 
69.75 (2.79) 
64.41 (2.41) 
% Body Fat 
    Males 
    Females 
541 
268 
273 
28.79 (8.85) 
23.78 (6.77) 
33.69 (7.85) 
436 
212 
224 
29.71 (9.21) 
25.37 (7.01) 
33.81 (9.17) 
103 
54 
49 
30.01 (8.86) 
25.23 (7.20) 
35.27 (7.44) 
Fat Free Mass (pounds) 
    Males 
    Females 
541 
268 
273 
122.01 (26.36)
145.27 (14.83)
99.18 (10.37) 
436 
212 
224 
122.14 (26.28)
144.41 (17.46)
101.06 (11.84)
103 
54 
49 
123.51 (26.99) 
145.32 (17.40) 
99.48 (9.47) 
Waist Circumference (inches) 
    Males 
    Females 
541 
269 
272 
35.60 (5.79) 
38.61 (5.03) 
32.62 (4.88) 
437 
213 
224 
36.16 (6.61) 
39.33 (5.52) 
33.15 (6.14) 
103 
54 
49 
36.66 (5.75) 
39.37 (5.49) 
33.66 (4.43) 
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Subject Characteristics by MC4R-4599 T>G 2-Group Genotype 
  TT TG + GG 
  N Mean (S.D.) N Mean (S.D.) 
Age (years) 
    Males 
    Females 
542 
269 
273 
44.90 (6.83) 
44.42 (7.06) 
45.38 (6.57) 
540 
267 
273 
44.47 (6.74) 
44.69 (6.69) 
44.26 (6.79) 
BMI (kg/m2) 
    Males 
    Females 
542 
269 
273 
26.65 (6.83) 
27.43 (4.65) 
25.88 (5.17) 
539 
266 
273 
27.37 (5.60) 
28.23 (4.69) 
26.54 (6.26) 
Weight (pounds) 
    Males 
    Females 
542 
269 
273 
172.75 (38.34)
193.06 (33.26)
152.74 (31.99)
540 
267 
273 
177.02 (43.22) 
196.92 (38.74) 
157.55 (38.27) 
Height (inches) 
    Males 
    Females 
542 
269 
273 
67.39 (3.94) 
70.38 (2.54) 
64.45 (2.65) 
540 
267 
273 
67.20 (3.69) 
69.84 (2.69) 
64.62 (2.54) 
% Body Fat 
    Males 
    Females 
541 
268 
273 
28.79 (8.85) 
23.78 (6.77) 
33.69 (7.85) 
539 
266 
273 
29.76 (9.13) 
25.34 (7.04) 
34.07 (8.89) 
Fat Free Mass (pounds) 
    Males 
    Females 
541 
268 
273 
122.01 (26.36)
145.27 (14.83)
99.18 (10.37) 
539 
266 
273 
122.40 (26.40) 
144.60 (17.42) 
100.77 (11.46) 
Waist Circumference (inches) 
    Males 
    Females 
541 
269 
272 
35.60 (5.79) 
38.61 (5.03) 
32.62 (4.88) 
540 
267 
273 
36.26 (6.45) 
39.34 (5.51) 
33.24 (5.87) 
 
Subject Characteristics by MC4R-4850 T>C Genotype 
  TT TC CC 
  N Mean (S.D.) N Mean (S.D.) N Mean (S.D.) 
Age (years) 
    Males 
    Females 
628 
308 
320 
45.04 (6.87) 
44.63 (7.09) 
45.43 (6.65) 
380 
193 
187 
44.17 (6.78) 
44.59 (6.67) 
44.73 (6.89) 
62 
28 
34 
44.29 (5.99) 
43.46 (6.39) 
44.97 (5.65) 
BMI (kg/m2) 
    Males 
    Females 
628 
308 
320 
26.78 (5.20) 
27.45 (4.71) 
26.13 (5.55) 
379 
192 
187 
27.32 (5.63) 
28.25 (4.51) 
26.36 (6.45) 
62 
28 
34 
27.89 (4.96) 
28.95 (5.12) 
27.02 (4.72) 
Weight (pounds) 
    Males 
    Females 
628 
308 
320 
173.19 (39.08)
192.76 (34.27)
154.36 (33.86)
380 
193 
187 
177.12 (43.80)
197.00 (38.05)
156.60 (39.78)
62 
28 
34 
179.65 (41.52) 
203.36 (41.59) 
160.13 (30.04)
Height (inches) 
    Males 
    Females 
628 
308 
320 
67.33 (3.90) 
70.28 (2.59) 
64.49 (2.65) 
380 
193 
187 
67.23 (3.68) 
69.77 (2.68) 
64.61 (2.56) 
62 
28 
34 
67.13 (3.76) 
70.19 (2.74) 
64.60 (2.33) 
% Body Fat 
    Males 
    Females 
627 
307 
320 
28.99 (9.08) 
23.81 (6.86) 
33.96 (8.12) 
379 
192 
187 
29.49 (8.99) 
25.48 (6.80) 
33.62 (9.11) 
62 
28 
34 
31.24 (9.12) 
25.86 (8.18) 
35.68 (7.35) 
Fat Free Mass (pounds) 
    Males 
    Females 
627 
307 
320 
121.78 (26.21)
144.90 (15.12)
99.60 (10.99) 
379 
192 
187 
122.86 (26.61)
144.49 (17.79)
100.65 (11.63)
62 
28 
34 
122.20 (26.76) 
147.91 (16.60) 
101.03 (8.67) 
Waist Circumference (inches) 
    Males 
    Females 
627 
308 
319 
35.64 (5.86) 
38.56 (5.09) 
32.82 (5.12) 
380 
193 
187 
36.30 (6.58) 
39.41 (5.41) 
33.08 (6.14) 
62 
28 
34 
36.78 (6.29) 
39.68 (6.38) 
34.40 (5.18) 
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Subject Characteristics by MC4R-4850 T>C Genotype 
  TT TC + CC 
  N Mean (S.D.) N Mean (S.D.) 
Age (years) 
    Males 
    Females 
628 
308 
320 
45.04 (6.87) 
44.63 (7.09) 
45.43 (6.65) 
442 
221 
221 
44.18 (6.67) 
44.44 (6.63) 
43.92 (6.72) 
BMI (kg/m2) 
    Males 
    Females 
628 
308 
320 
26.78 (5.20) 
27.45 (4.71) 
26.13 (5.55) 
441 
220 
221 
27.40 (5.54) 
28.34 (4.59) 
26.46 (6.21) 
Weight (pounds) 
    Males 
    Females 
628 
308 
320 
173.19 (39.08)
192.76 (34.27)
154.36 (33.86)
442 
221 
221 
177.47 (43.45) 
197.80 (38.47) 
157.15 (38.40) 
Height (inches) 
    Males 
    Females 
628 
308 
320 
67.33 (3.90) 
70.28 (2.59) 
64.49 (2.65) 
442 
221 
221 
67.22 (3.69) 
69.82 (2.69) 
64.61 (2.52) 
% Body Fat 
    Males 
    Females 
627 
307 
320 
28.99 (9.08) 
23.81 (6.86) 
33.96 (8.12) 
441 
220 
221 
29.74 (9.01) 
25.53 (6.97) 
33.93 (8.88) 
Fat Free Mass (pounds) 
    Males 
    Females 
627 
307 
320 
121.78 (26.21)
144.90 (15.12)
99.60 (10.99) 
441 
220 
221 
122.77 (26.60) 
144.93 (17.64) 
100.71 (11.21) 
Waist Circumference (inches) 
    Males 
    Females 
627 
308 
319 
35.64 (5.86) 
38.56 (5.09) 
32.82 (5.12) 
442 
221 
221 
36.37 (6.54) 
39.45 (5.53) 
33.28 (6.01) 
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HISTOGRAMS 
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